Clinical Trials
222
15 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
11
5.0%
Completed
126
56.8%
Enrolling By Invitation
1
0.5%
Not yet recruiting
3
1.4%
Recruiting
28
12.6%
Terminated
9
4.0%
Unknown
42
18.9%
Withdrawn
2
0.9%
No approval data available
- Researchers at LMU have developed a novel hybrid polymer nanocarrier system combining PLGA and PBAEs for effective inhalable mRNA vaccine delivery. - The hybrid nanoparticles successfully overcome lung barriers, penetrate airway mucus, and efficiently transfect immune cells for robust immune activation. - The system demonstrates superior robustness during aerosolization compared to clinically approved lipid nanoparticles, maintaining higher transfection efficiency after nebulization. - Testing in human precision-cut lung slices confirms the platform's potential as a promising alternative for next-generation pulmonary mRNA vaccines.
- Researchers at LMU Munich have created Bits2Bonds, the first integrated platform combining molecular dynamics simulations and machine learning to identify new polymeric materials for therapeutic RNA delivery. - The computational tool enables rapid virtual screening of thousands of potential carrier molecules before experimental validation, dramatically accelerating the discovery of effective and safe RNA nanocarriers. - The team validated their computational predictions by synthesizing and testing polymer candidates for siRNA delivery, confirming strong correlation between simulated performance and biological efficacy. - The modular pipeline can be adapted to other nucleic acid modalities including mRNA and CRISPR-based therapies, paving the way for personalized RNA medicines.
